Back to Search
Start Over
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- Source :
- The Lancet; December 2019, Vol. 394 Issue: 10214 p2096-2107, 12p
- Publication Year :
- 2019
-
Abstract
- Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 394
- Issue :
- 10214
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs51561126
- Full Text :
- https://doi.org/10.1016/S0140-6736(19)32556-5